Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21)

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 604-607

  Wang, Ying ^a   Li, Weiyang ^a   Chen, Suning ^a   Qiu, Huiying ^a   Sun, Aining ^a   Wu, Depei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Aclarubicin; Acute myeloid leukemia; Cytarabine; Granulocyte colony stimulating factor; T(8 ; 21)

Indexed keywords

ACLARUBICIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; GENZYME; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; SEMUSTINE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CENTRAL LINE INFECTION; CHILD; CHROMOSOME 21; CHROMOSOME 8; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PERIANAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALVAGE THERAPY; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING;

ACLARUBICIN; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 79954613932     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.003     Document Type: Article

References (25)

1. Dombret H., Preudhomme C., Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. Curr Opin Hematol 2009, 16:92-97.
2. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22:3741-3750.
3. Marcucci G., Mrozek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:5705-5717.
4. Kuwatsuka Y., Miyamura K., Suzuki R., et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood 2009, 113:2096-2103.
5. Mato A.R., Morgans A., Luger S.M. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2008, 15:108-114.
6. Tafuri A., Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990, 4:826-834.
7. Bai A., Kojima H., Hori M., et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999, 27:259-265.
8. Ohno R., Naoe T., Kanamaru A., et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood 1994, 83:2086-2092.
9. Löwenberg B., van Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
10. Yamada K., Furusawa S., Saito K., et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995, 9:10-14.
11. Saito K., Nakamura Y., Aoyagi M., et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000, 71:238-244.
12. Qian S.X., Li J.Y., Tian T., et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007, 31:1383-1388.
13. Shimizu K., Kitabayashi I., Kamada N., et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 2000, 96:288-296.
14. Moon H.W., Shin S., Kim H.Y., et al. Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia 2006, 20:1408-1413.
15. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria version 3.0. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
16. Litzow M.R. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007, 14:130-137.
17. Kern W., Schoch C., Haferlach T., et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000, 14:226-231.
18. Borthakur G., Kantarjian H., Wang X., et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008, 113:3181-3185.
19. Thomas X., Raffoux E., Botton S., et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007, 21:453-461.
20. Pelizzari A.M., Drera M., D'Adda M., et al. Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients. Haematologica 2007, 92:106-109.
21. Mrózek K., Bloomfield C.D. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2006, 169-177.
22. Mrózek K., Marcucci G., Paschka P., et al. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008, 20:711-718.
23. Shih L.Y., Liang D.C., Huang C.F., et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008, 22:303-307.
24. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
25. Barker J.N., Krepski T.P., DeFor T.E., et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002, 8:257-260.